CLL: Treatment and Management Strategies for Best Outcomes - Episode 15
Treatment Decisions in R/R CLL
June 12, 2024
A medical oncologist provides a comprehensive overview of treatment options for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK inhibitors and CAR T-cell therapy.
Video content above is prompted by the following question(s):
- For patients with R/R disease, please discuss your approach to treatment.
- How do you choose between BTKi in the R/R setting (please provide brief, high-level overview of the data for patients)?
- Zanubrutinib vs ibrutinib (ALPINE Extended Follow-up ASH 2023 (Brown NEJM 2023)
- Acalabrutinib vs ibruitinib(ELEVATE-RR Byrd J Clin Oncol, 2021) (ELEVATE RR 4-year Follow-up
- What is the role forvenetoclax in the R/R Setting?
- If a patient fails on one treatment, how do you approach sequencing decisions?
Related Content:
